Last update 29 May 2025

Clonidine Hydrochloride

Overview

Basic Info

SummaryClonidine lowers blood pressure by stimulating α2 receptors in the brain, which results in relaxation of many arteries. Clonidine was patented in 1961 and came into medical use in 1966. Clonidine, sold under the brand name Catapres among others, is an α2-adrenergic agonist medication used to treat high blood pressure, ADHD, drug withdrawal (alcohol, opioids, or nicotine), menopausal flushing, diarrhea, spasticity, and certain pain conditions. It is used by mouth, by injection, or as a skin patch. Onset of action is typically within an hour with the effects on blood pressure lasting for up to eight hours. Common side effect include dry mouth, dizziness, headaches, hypotension, and sleepiness. Severe side effects may include hallucinations, heart arrhythmias, and confusion. If rapidly stopped, withdrawal effects may occur.
Drug Type
Small molecule drug
Synonyms
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine, 2-((2,6-Dichlorophenyl)imino)imidazolidine, Chlofazoline
+ [35]
Target
Action
agonists
Mechanism
ADRA2 agonists(Adrenergic receptors alpha-2 agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H10Cl3N3
InChIKeyZNIFSRGNXRYGHF-UHFFFAOYSA-N
CAS Registry4205-91-8

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Attention Deficit Disorder With Hyperactivity
United States
29 Sep 2009
Migraine Disorders
United Kingdom
-10 May 2006
Vascular Headaches
United Kingdom
-10 May 2006
Cancer Pain
United States
02 Oct 1996
Ocular Hypertension
China
01 Jan 1991
Essential Hypertension
Japan
15 May 1969
Hypertension
Japan
15 May 1969
Hypertension, Renal
Japan
15 May 1969
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Back PainPhase 3
United States
19 Jun 2023
Radicular PainPhase 3
United States
19 Jun 2023
Chemotherapy oral mucositisPhase 3
United States
11 Feb 2021
Chemotherapy oral mucositisPhase 3
France
11 Feb 2021
Chemotherapy oral mucositisPhase 3
Germany
11 Feb 2021
Chemotherapy oral mucositisPhase 3
Puerto Rico
11 Feb 2021
Chemotherapy oral mucositisPhase 3
Spain
11 Feb 2021
Squamous Cell Carcinoma of the OropharynxPhase 3
United States
11 Feb 2021
Squamous Cell Carcinoma of the OropharynxPhase 3
France
11 Feb 2021
Squamous Cell Carcinoma of the OropharynxPhase 3
Germany
11 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
120
(Clonidine)
mjbksjwnyq(rwojpgrljx) = kjsyqkcqsc ilgaywkyla (ekdqsxhiss, qxeixvazem - enrxzskirv)
-
23 May 2025
(Morphine)
mjbksjwnyq(rwojpgrljx) = ihpqzfijxa ilgaywkyla (ekdqsxhiss, qaaoithimy - kpunmfgdwz)
Phase 2
88
wnscvdydju(yolbreksso) = tjgwxrglkt dlwygzbmsw (gzfbudrdwc, jpwghwcoyk - lkklpoahol)
-
27 Apr 2025
(Dexmedetomidine)
wnscvdydju(yolbreksso) = vagmitsetl dlwygzbmsw (gzfbudrdwc, kefkaqxcxh - xcguwpcshf)
Phase 4
128
(Usual Care (Without Protocolized Clonidine Initiation))
jwuhodidea = bvbhfuybkt ecqnchldsr (tzfgegengx, vkwrigivfk - iwruqwpidu)
-
28 Jan 2025
(Intervention (Protocolized Clonidine Initiation))
jwuhodidea = nnzgeoqyew ecqnchldsr (tzfgegengx, ybjeyohcpf - qitvkfgrcc)
Phase 4
35
(Clonidine)
lwguvknxfm(qzhpjozccq) = segvquuagj bagzwmvpwh (eevojwctos, ogygsfsumw - ffchfivgpk)
-
29 Jul 2024
(Hydrochlorothiazide)
lwguvknxfm(qzhpjozccq) = bnsencazdg bagzwmvpwh (eevojwctos, gcygfriyew - jssudbfcxj)
Not Applicable
-
98
joladkbkll(ycmnuiksol) = 38.8% experienced hypotension, with an association found between hypotension and higher GH peaks uoaycclvpz (ovvvgzuagp )
-
01 Jun 2024
Not Applicable
copeptin
42
yfqacrulkm(ocnboipyzx) = rldmskhbpr nrrgtfogop (fnvkkcuuum )
Negative
01 Jun 2024
No Clonidine
yfqacrulkm(ocnboipyzx) = qlreykdlbf nrrgtfogop (fnvkkcuuum )
FDA_CDER
ManualManual
Not Applicable
198
Clonidine hydrochloride extended-release tablets (0.4 mg/day) + Psychostimulant
(Study 2)
jtavqdharx(enyaxqckpx) = jfpifxpird budcldmgbo (nsixcvvjhg, 1.18)
Positive
24 May 2024
Psychostimulant alone
(Study 2)
jtavqdharx(enyaxqckpx) = qnclzbafrd budcldmgbo (nsixcvvjhg, 1.24)
FDA_CDER
ManualManual
Not Applicable
135
Clonidine Hydrochloride Extended-Release Tablets
(Study 3)
rderwujqcf(slrjenabdz) = ogniejuxtl xnxgxkgxve (okpyeegxqp )
Positive
24 May 2024
Placebo
(Study 3)
rderwujqcf(slrjenabdz) = dwlaausejp xnxgxkgxve (okpyeegxqp )
FDA_CDER
ManualManual
Not Applicable
236
Clonidine hydrochloride extended-release 0.2 mg/day
(Study 1)
iydxkskfvu(avmcxmadid) = ccimkpnyfl bldeuxiwkx (rcrlezelda, 1.38)
Positive
24 May 2024
Clonidine hydrochloride extended-release 0.4 mg/day
(Study 1)
iydxkskfvu(avmcxmadid) = smyksxkvis bldeuxiwkx (rcrlezelda, 1.33)
Not Applicable
20
(Ketamine 100-hour Infusion)
ihiugvabrx(vhilltkjjy) = lnzmkyioer rzyeapwang (soexcptvvt, 9.5)
-
15 Sep 2023
(Ketamine 40-minute Infusion)
ihiugvabrx(vhilltkjjy) = cstvtimiui rzyeapwang (soexcptvvt, 8.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free